Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis

References

• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13(4–5):496–502.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725.
   PubMed Web of Science ®Google Scholar
• Ben Abdallah H, Johansen C, Iversen L. Key signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics. Psoriasis (Auckl). 2021;11:83–97.
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119.
   PubMed Web of Science ®Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, et al. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl). 2018;8:1–5.
   PubMed Web of Science ®Google Scholar
• Tremfya: EPAR - product information [Internet]. European Medicines Agency (EMA); 2017. [cited 2021 August 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf
   Google Scholar
• Ilumetri: EPAR - product information [Internet]. European Medicines Agency (EMA); 2018. [cited 2021 August 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf
   Google Scholar
• Skyrizi: EPAR - product information [Internet]. European Medicines Agency (EMA); 2022. [cited 2022 March 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf
   Google Scholar
• Tremfya prescribing information [Internet]. US Food and Drug Administration; 2020. [cited 2022 March 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf
   Google Scholar
• Skyrizi prescribing information [Internet]. US Food and Drug Administration; 2022. [cited 2022 March 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761105s014lbl.pdf
   Google Scholar
• Ilumya prescribing information [Internet]. US Food and Drug Administration; 2018. [cited 2022 March 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf
   Google Scholar
• Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–59.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients With moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658.
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586.
   PubMed Web of Science ®Google Scholar
• Biological treatment in Danish dermatology [Internet]. Copenhagen: Copenhagen Healthtech Cluster; 2022. Available from: https://www.danishhealthdata.com/find-health-data/National-kvalitetsdatabase-for-psoriasispatienter-i-biologisk-behandling
   Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Zaaroura H, Mufti A, et al. Drug survival of guselkumab in patients with plaque psoriasis: a 2 year retrospective, multicenter study. JAAD Int. 2021;4:49–51.
   PubMedGoogle Scholar
• Egeberg A, Rosenø NAL, Aagaard D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective Multi-Country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579.
   PubMed Web of Science ®Google Scholar
• Iznardo H, Vilarrasa E, López-Ferrer A, et al. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol. 2021;185(3):660–662.
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, et al. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2):e14798.
   PubMed Web of Science ®Google Scholar
• Dapavo P, Siliquini N, Mastorino L, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2021;13:1–6.
   Google Scholar
• Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated With effectiveness and safety of treatment With guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients With psoriasis. JAMA Dermatol. 2022;e222909.
   Web of Science ®Google Scholar
• Schwensen JFB, Nielsen VW, Nissen CV, et al. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol. 2021;35(5):e341–e343.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868.
   PubMed Web of Science ®Google Scholar
• Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173–192.
   PubMed Web of Science ®Google Scholar
• Danish Medicines Council [Internet]. Copenhagen: Danish medicines council. [cited 2022 Jul 14]. Available from: https://medicinraadet.dk/om-os/in-english
   Google Scholar
• Zweegers J, Roosenboom B, van de Kerkhof PC, et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol. 2017;176(3):786–793.
   PubMed Web of Science ®Google Scholar
• Burlando M, Castelli R, Cozzani E, et al. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:1–4.
   Google Scholar
• Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.
   PubMed Web of Science ®Google Scholar
• Megna M, Fabbrocini G, Cinelli E, et al. Guselkumab in moderate to severe psoriasis in routine clinical care: an italian 44-week real-life experience. J Dermatolog Treat. 2020;4:1–5.
   Google Scholar
• Zhuang JY, Li JS, Zhong YQ, et al. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: a prospective real-life study on the Chinese population. Dermatol Ther. 2021;34(5):e15054.
   PubMed Web of Science ®Google Scholar
• Hansel K, Zangrilli A, Bianchi L, et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021;35(3):e169–e170.
   PubMed Web of Science ®Google Scholar
• Benhadou F, Ghislain PD, Guiot F, et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(12):e837–e839. Dec
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Cetkovska P, Arenberger P, et al. Risankizumab for the treatment of moderate-to-Severe psoriasis: real-life multicenter experience from the Czech Republic. Dermatol Ther (Heidelb). 2021;11(4):1345–1355.
   PubMed Web of Science ®Google Scholar
• Fougerousse AC, Ghislain PD, Reguiai Z, et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020;34(10):e644–e646. Oct
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Gallo L, et al. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–623.
   PubMed Web of Science ®Google Scholar
• Puig L, Dossenbach M, Berggren L, et al. Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol. 2019;99(11):971–977.
   PubMed Web of Science ®Google Scholar
• Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633–639.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63(4):571–579.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and Meta-analysis. PLoS One. 2018;13(5):e0195123.
   PubMed Web of Science ®Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007–1011.
   PubMed Web of Science ®Google Scholar
• Kyntheum: EPAR - assessment report [Internet]: European Medicines Agency (EMA); 2017. [cited 2022 September]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/kyntheum-epar-public-assessment-report_en.pdf
   Google Scholar
• Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942–954.
   PubMed Web of Science ®Google Scholar
• van den Reek J, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5.
   PubMed Web of Science ®Google Scholar